Patents by Inventor Toufic Osman Nashar

Toufic Osman Nashar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic Agents
    Publication number: 20140322274
    Abstract: A method for treating an rheumatoid arthritis in a mammalian subject in need of same wherein the method comprises: administering to the mammalian subject an agent capable of modulating a ganglioside GM-1 associated activity in an amount effective to treat the disease.
    Type: Application
    Filed: December 10, 2013
    Publication date: October 30, 2014
    Inventors: Neil Andrew Williams, Timothy Raymond Hirst, Toufic Osman Nashar
  • THERAPEUTIC AGENTS
    Publication number: 20100136023
    Abstract: A method for treating an rheumatoid arthritis in a mammalian subject in need of same wherein the method comprises: administering to the mammalian subject an agent capable of modulating a ganglioside GM-1 associated activity in an amount effective to treat the disease.
    Type: Application
    Filed: September 14, 2009
    Publication date: June 3, 2010
    Applicant: TRIDENT PHARMACEUTICALS, INC.
    Inventors: NEIL ANDREW WILLIAMS, TIMOTHY RAYMOND HIRST, TOUFIC OSMAN NASHAR
  • Methods for the prevention against or treatment of diabetes with ETXB and/or insulin
    Patent number: 7588763
    Abstract: This application relates to methods for modulating an immune response in a mammalian subject in need of prevention against or treatment of diabetes comprising the administration of EtxB and/or insulin.
    Type: Grant
    Filed: September 30, 2005
    Date of Patent: September 15, 2009
    Assignee: Trident Pharmaceuticals, Inc.
    Inventors: Neil Andrew Williams, Timothy Raymond Hirst, Toufic Osman Nashar
  • Therapeutic agents
    Publication number: 20010036917
    Abstract: A method for treating diabetes in a mammalian subject in need of same wherein the method comprises: administering to the mammalian subject an agent capable of modulating a ganglioside GM-1 (GM-1) associated activity in an amount effect to treat the disease; wherein the agent, when in vivo, has an effect on GM-1 mediated intracellular signalling events; and wherein if the agent is for co-administration with an antigen, then the agent and the antigen are not so linked to form a single active agent.
    Type: Application
    Filed: May 30, 2001
    Publication date: November 1, 2001
    Inventors: Neil Andrew Williams, Timothy Raymond Hirst, Toufic Osman Nashar
  • Therapeutic agents and autoimmune diseases
    Patent number: 6287563
    Abstract: There is disclosed the use, as an agent in the treatment or the prevention of an autoimmune disease, of: (i) an agent having GM-1 binding activity, other than Ctx or Etx, or the B subunits of Ctx and Etx; or (ii) an agent having an effect on GM-1 mediated intracellular signalling events, but no GM-1 binding activity. These agents may also be used in the treatment of human T cell leukaemia, in the prevention of transplant rejection or GVHD or in a vaccination method for vaccinating a mammalian subject.
    Type: Grant
    Filed: December 29, 1997
    Date of Patent: September 11, 2001
    Inventors: Neil Andrew Williams, Timothy Raymond Hirst, Toufic Osman Nashar